Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Baxter International Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Perspective Therapeutics (CATX – Research Report), Baxter Interna...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Perspective Therapeutics (CATX), Baxter International (BAX) and Arvinas Holding Company (ARVN)

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Baxter International, with a price target of $25.00. Miksic covers...

Current Quarter	$0.32	Next Quarter	$0.45
Current Year	$1.92	Next Year	$2.04
QoQ Growth	+40.6%	YoY Growth	+6.3%
3Y EPS CAGR	-35.6%	Target Price	$20.50
Consensus	Buy	Upside	+18.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BAX	$17.30	+0.35%	5.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BAX	$17.30	+0.3%	5.44M
3
4
5
6

BAX

BAX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Baxter International Inc. Data in Excel

Get Baxter International Inc. Data in Excel